DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, Ara | ko |
dc.contributor.author | Sim, Nam Suk | ko |
dc.contributor.author | Choi, Han Som | ko |
dc.contributor.author | Yang, Donghwa | ko |
dc.contributor.author | Kim, Se Hee | ko |
dc.contributor.author | Lee, Joon Soo | ko |
dc.contributor.author | Kim, Dong Seok | ko |
dc.contributor.author | Lee, Jeong Ho | ko |
dc.contributor.author | Kim, Heung Dong | ko |
dc.contributor.author | Kang, Hoon-Chul | ko |
dc.date.accessioned | 2022-01-18T06:41:09Z | - |
dc.date.available | 2022-01-18T06:41:09Z | - |
dc.date.created | 2022-01-18 | - |
dc.date.created | 2022-01-18 | - |
dc.date.created | 2022-01-18 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.citation | JOURNAL OF CLINICAL NEUROLOGY, v.18, no.1, pp.71 - 78 | - |
dc.identifier.issn | 1738-6586 | - |
dc.identifier.uri | http://hdl.handle.net/10203/291854 | - |
dc.description.abstract | Background and Purpose A multifactorial antiepileptic mechanism underlies the ketogenic diet (KD), and one of the proposed mechanisms of action is that the KD inhibits the mammalian target of rapamycin (mTOR) pathway. To test this clinically, this study aimed to determine the efficacy of the KD in patients with pathologically confirmed focal cortical dysplasia (FCD) due to genetically identifiable mTOR pathway dysregulation. Methods A cohort of patients with pathologically confirmed FCD after epilepsy surgery and who were screened for the presence of germline and somatic mutations related to the mTOR pathway in peripheral blood and resected brain tissue was constructed prospectively. A retrospective review of the efficacy of the prior KD in these patients was performed. Results Twenty-five patients with pathologically confirmed FCD and who were screened for the presence of detectable somatic mTOR pathway mutations had received a sufficient KD. Twelve of these patients (48.0%) had germline or somatic detectable mTOR pathway mutations. A response was defined as a =50% reduction in seizure frequency. The efficacy of the KD after 3 months of dietary therapy was superior in patients with detectable mTOR pathway mutations than in patients without detectable mTOR pathway mutations, although the difference was not statistically significant (responder rates of 58.3% vs. 38.5%, p=0.434). Conclusions A greater proportion of patients with mTOR pathway responded to the KD, but there was no statistically significant difference in efficacy of the KD between patients with and without detectable mTOR pathway mutations. Further study is warranted due to the smallness of the sample and the limited number of mTOR pathway genes tested in this study. | - |
dc.language | English | - |
dc.publisher | KOREAN NEUROLOGICAL ASSOC | - |
dc.title | Efficacy of the Ketogenic Diet for Pediatric Epilepsy According to the Presence of Detectable Somatic mTOR Pathway Mutations in the Brain | - |
dc.type | Article | - |
dc.identifier.wosid | 000740913000010 | - |
dc.identifier.scopusid | 2-s2.0-85123062907 | - |
dc.type.rims | ART | - |
dc.citation.volume | 18 | - |
dc.citation.issue | 1 | - |
dc.citation.beginningpage | 71 | - |
dc.citation.endingpage | 78 | - |
dc.citation.publicationname | JOURNAL OF CLINICAL NEUROLOGY | - |
dc.identifier.doi | 10.3988/jcn.2022.18.1.71 | - |
dc.identifier.kciid | ART002797313 | - |
dc.contributor.localauthor | Lee, Jeong Ho | - |
dc.contributor.nonIdAuthor | Ko, Ara | - |
dc.contributor.nonIdAuthor | Choi, Han Som | - |
dc.contributor.nonIdAuthor | Yang, Donghwa | - |
dc.contributor.nonIdAuthor | Kim, Se Hee | - |
dc.contributor.nonIdAuthor | Lee, Joon Soo | - |
dc.contributor.nonIdAuthor | Kim, Dong Seok | - |
dc.contributor.nonIdAuthor | Kim, Heung Dong | - |
dc.contributor.nonIdAuthor | Kang, Hoon-Chul | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | mammalian target of rapamycin | - |
dc.subject.keywordAuthor | epilepsy | - |
dc.subject.keywordAuthor | focal cortical dysplasia | - |
dc.subject.keywordAuthor | mTORopathies | - |
dc.subject.keywordAuthor | somatic mutation | - |
dc.subject.keywordAuthor | ketogenic diet | - |
dc.subject.keywordPlus | POLYUNSATURATED FATTY-ACIDS | - |
dc.subject.keywordPlus | MODIFIED ATKINS DIET | - |
dc.subject.keywordPlus | MAMMALIAN TARGET | - |
dc.subject.keywordPlus | TUBEROUS SCLEROSIS | - |
dc.subject.keywordPlus | PHARMACOLOGICAL INHIBITION | - |
dc.subject.keywordPlus | GLUTAMATE TRANSPORT | - |
dc.subject.keywordPlus | CHILDHOOD EPILEPSY | - |
dc.subject.keywordPlus | SIGNALING PATHWAY | - |
dc.subject.keywordPlus | MOUSE MODEL | - |
dc.subject.keywordPlus | RAPAMYCIN | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.